Refine
Year of publication
Document Type
- Article (28)
- Doctoral Thesis (7)
Language
- English (35) (remove)
Has Fulltext
- yes (35)
Is part of the Bibliography
- no (35)
Keywords
- - (15)
- Mas receptor (2)
- PSMC5 (2)
- Thioredoxine (2)
- autoinflammation (2)
- proteasome (2)
- proteasomopathy (2)
- redox signaling (2)
- thermodynamics (2)
- 1-MT (1)
- ACE2 (1)
- APP (1)
- Abdominal fat (1)
- Acute decompensated heart failure (1)
- Alzheimer's disease (1)
- Antibacterial host defense (1)
- B-Zelle (1)
- Biochemie (1)
- CANDLE (1)
- CD13 (1)
- COVID-19 (1)
- CRMP2 (1)
- Chagas’ disease (1)
- Collapsin Response Mediator Protein 2 (1)
- Congestion (1)
- DNA (1)
- Doxorubicin (1)
- Entwicklungsstörung (1)
- G-quadruplexes (1)
- Gen (1)
- Glutaredoxin (1)
- Glutaredoxin 2 (1)
- Glutaredoxine (1)
- Glutathion (1)
- Glutathione (1)
- IDO (1)
- Immunosuppression (1)
- Inferior vena cava (1)
- Inflammation (1)
- Influenza A virus (1)
- Insulin (1)
- Intelligenzminderung (1)
- Interleukin-37 (1)
- Islets of Langerhans (1)
- KYNA (1)
- LA-, HA-MRSA (1)
- Langerhans-Inseln (1)
- Leptin (1)
- M1 macrophage (1)
- M2 macrophage (1)
- MICAL (1)
- MSSA (1)
- Mas Rezeptor (1)
- MiD51 (1)
- Mitochondrium (1)
- Molekularbiologie (1)
- Mutation (1)
- NADPH oxidase (1)
- NF-κB signal transduction pathway (1)
- NT‐proBNP (1)
- Neurologie (1)
- Nrf2-sinaling (1)
- Oxidative burst (1)
- Oxidoreduktase (1)
- PRAAS (1)
- PSMA5 (1)
- PSMB10 (1)
- PSMB8 (1)
- Pancreatic Beta-Cell (1)
- Phagocytosis (1)
- Phosphorylierung (1)
- Pneumococcal pneumonia (1)
- Posttranslationale Modifikation (1)
- Prostatakarzinom (1)
- Proteasom (1)
- Proteasom-Assoziierte Störungen (1)
- Proteinbiochemie (1)
- Proteine (1)
- RAAS (1)
- ROS (1)
- Reactive oxygen species (1)
- Redoxregulation (1)
- Renin-Angiotensin System (1)
- Renin-Angiotensin-System (1)
- SDS-SP3 protocol (1)
- Signalwege (1)
- Sonic Hedgehog signaling (1)
- Syndrom (1)
- TLR4 signaling (1)
- TPD52 (1)
- Tau (1)
- Thiole (1)
- Thyroid function (1)
- Thyroid-stimulating hormone (1)
- Tumorbiologie (1)
- Ultrasound (1)
- Visceral adipose tissue (1)
- Visceral body fat (1)
- Vitamin B6 deficiency (1)
- Wnt-signaling (1)
- Zellmigration (1)
- Zytoskelett (1)
- [Fe-S] Cluster (1)
- acute kidney injury (1)
- airway inflammation (1)
- angiotensin (1)
- angiotensin 1-7 (1)
- antioxidant signaling pathways (1)
- asthma (1)
- atrial fibrillation (1)
- autoimmune (1)
- biofilm (1)
- calorimetry (1)
- cancer (1)
- cancer stem cell (1)
- cardiolipin composition (1)
- catalytic activity (1)
- codon (1)
- collapsin response mediator protein 2 (1)
- cystic fibrosis (1)
- cytotoxicity (1)
- de novo mutations (1)
- drug resistance (1)
- eicosanoids (1)
- enzyme (1)
- extravasation (1)
- formalin fixed and embedded brain sample (1)
- geistige Behinderung (1)
- gene library (1)
- glutaredoxin 2 (1)
- glutaredoxins (1)
- glutathione (1)
- hemolysis (1)
- idiopathic dilated cardiomyopathy (1)
- immunity (1)
- infection (1)
- inflammation (1)
- integrated stress response (1)
- intellectual disability (1)
- interferon (1)
- interferonopathy (1)
- invasion (1)
- katalytische Aktivität (1)
- kinetics (1)
- kynurenine pathway (1)
- lipid mediator (1)
- mass spectrometry (1)
- microvascular flow (1)
- mitochondrial dynamics (1)
- mitochondrial fission (1)
- mitochondrial respiration (1)
- mitophagy (1)
- mutations (1)
- neurodegeneration (1)
- neurodevelopmental disorders (1)
- neutrophil (1)
- oxidative dysbalance (1)
- oxidative stress (1)
- oxidoreductase (1)
- pancreatic beta cells (1)
- pig (1)
- posttranslational modification (1)
- prostate cancer (1)
- proteasome associated autoinflammatory syndrome (1)
- proteasome-associated autoinflammatory syndrome (1)
- proteasomes (1)
- protein biochemistry (1)
- protein engineering (1)
- protein preparation (1)
- proteostasis (1)
- randomization (1)
- reactive oxygen species (1)
- reactive oxygen species (ROS) (1)
- redox (1)
- redox metabolism (1)
- redox relay (1)
- signalling pathways (1)
- syndromic (1)
- topology (1)
- trinucleotide building block (1)
- tryptophan (1)
- type I interferon (1)
- ubiquitin (1)
- ubiquitin–proteasome system (1)
- unfolded protein response (1)
- virulence (1)
Institute
- Institut für Med. Biochemie u. Molekularbiologie (35) (remove)
Publisher
- Frontiers Media S.A. (9)
- MDPI (9)
- S. Karger AG (2)
- Springer Nature (2)
- Wiley (2)
- American Society for Microbiology (ASM) (1)
- Elsevier (1)
- Public Library of Science (PLoS) (1)
- SAGE Publications (1)
Type I interferonopathies cover a phenotypically heterogeneous group of rare genetic diseases including the recently described proteasome-associated autoinflammatory syndromes (PRAAS). By definition, PRAAS are caused by inherited and/or de novo loss-of-function mutations in genes encoding proteasome subunits such as PSMB8, PSMB9, PSMB7, PSMA3, or proteasome assembly factors including POMP and PSMG2, respectively. Disruption of any of these subunits results in perturbed intracellular protein homeostasis including accumulation of ubiquitinated proteins which is accompanied by a type I interferon (IFN) signature. The observation that, similarly to pathogens, proteasome dysfunctions are potent type I IFN inducers is quite unexpected and, up to now, the underlying molecular mechanisms of this process remain largely unknown. One promising candidate for triggering type I IFN under sterile conditions is the unfolded protein response (UPR) which is typically initiated in response to an accumulation of unfolded and/or misfolded proteins in the endoplasmic reticulum (ER) (also referred to as ER stress). The recent observation that the UPR is engaged in subjects carrying POMP mutations strongly suggests its possible implication in the cause-and- effect relationship between proteasome impairment and interferonopathy onset. The purpose of this present review is therefore to discuss the possible role of the UPR in the pathogenesis of PRAAS. We will particularly focus on pathways initiated by the four ER-membrane proteins ATF6, PERK, IRE1-a, and TCF11/Nrf1 which undergo activation under proteasome inhibition. An overview of the current understanding of the mechanisms and potential cross-talk between the UPR and inflammatory signaling casacades is provided to convey a more integrated picture of the pathophysiology of PRAAS and shed light on potential biomarkers and therapeutic targets.
Numerous signalling pathways orchestrate the development, the functions, and the survival of cells, mostly in response to external stimuli. An overwhelming amount of data supports the concept of specific, spatio-temporal redox signalling pathways that affect the redox state of protein cysteinyl side chains and thus the biological function of these proteins. Glutaredoxins (Grxs) and thioredoxins (Trxs) catalyse reversible thiol-disulphide exchange reactions. The cytosolic Grx2 isoform Grx2c is essential for brain development and axonal outgrowth. A reversible dithiol-disulphide switch of CRMP2 has been identified as one of the major targets regulated by Grx2c. This CRMP2 redox switch is toggled in neuronal differentiation. Reduction of CRMP2 thiols induces profound conformational changes, modifying interactions and downstream elements of this redox switch. In [article I] and [manuscript V], we identified the Cys504 of CRMP2 to be the redox regulated residue. We used various in vitro assays with recombinant protein and molecular dynamics simulations to characterise the conformational change. The changes involve the solvent accessible surface area of at least one known phosphorylation site at the C-terminus of the protein. In [article III], we analysed the function of Grx2 and Trx1 in a model for perinatal asphyxia. Trx family proteins exhibit a very complex, cell-type and tissue specific expression pattern following hypoxia/ischemia and reoxygenation, especially Trx1 and Grx2. The results imply the clinical relevance for both proteins in perinatal asphyxia as well as many other neurological disorders. In agreement with the results presented in [articleI], Grx2 may be required for the re-establishment of neuronal integrity and connectivity. Cell shape, all forms of intracellular transport, and cell movement depend on the cytoskeleton, particularly on the fine tuned complex regulation of the dynamic re-arrangement of actin filaments and microtubules. In [article IV], we discuss the redox regulation of this dynamic cytoskeletal remodelling. Taking recent discoveries into account, we focus on redox signalling mechanisms, e.g. reversible thiol and methionyl switches. These switches are specifically controlled by enzymes such as Trx1 and Grx2c, for instance, and not the result of random modification by unspecific oxidants. Methionyl sulphoxidation of actin can be reversed by methionyl sulphoxide reductase (MsrA), promoting actin polymerisation. Human cells express two different Msr enzymes (MsrA and MsrB), that can reduce S- and R-methionyl sulphoxide, respectively. In the gram-positive Streptococcus pneumoniae, on the other hand, both Msr genes and thus enzymes were fused during evolution. In [article II], we characterised the surface-exposed thioredoxin family lipoproteins Etrx1 and 2 and regulators of this Msr (SpMsrAB). A loss of function of both Etrx proteins or SpMsrAB dramatically reduced pneumococcal virulence, enhanced the bacterial uptake by macrophages, and accelerated pneumococcal killing by H2O2 or free methionine sulphoxide. Identification and characterisation of components of this redox regulated system may contribute to the design of new antimicrobials. In [manuscript VI], we investigated the effects of Grx2c expression on cell morphology, migration, and invasion behaviour of cancer cells. Grx2c expressing cancer cells developed dramatic changes in phenotype, including alterations in cytoskeletal dynamics and significantly increased motility and invasiveness. We used quantitative proteomics and phopshoproteomic approaches to characterise the underlying mechanisms. Proteins and pathways regulating cytoskeletal dynamics, cell adhesion, and receptor-mediated signal transduction were detected to be specifically altered. We started a clinical pilot study with patients suffering from clear cell renal cell carcinoma (ccRCC). Grx2c was expressed with significantly higher frequency in ccRCC compared to healthy kidney tissue, associated with a strong trend for locally more advanced tumour stages and a clear tendency for a decreased cancer-specific survival, compared to patients without detectable Grx2c. These results were supported by data from "The Cancer Genome Atlas". In synopsis, the results presented and discussed in these articles and manuscripts, support the concept of specific redox signalling in different models and model organisms. They also demonstrate the importance of the specific redox control of signalling pathways that, in the case of errors or misinterpretations, contribute to pathophysiological alterations. The regulation of the CRMP2 redox switch by Grx2c, for instance, is physiologically essential for brain development, but might lead to cancer progression, if "switched on" in adult tissue. Identification of further interaction partners as well as the development of compounds modulating this redox switch and CRMP2s conformations, will be part of our future research.
Despite their very close structural similarity, CxxC/S-type (class I) glutaredoxins (Grxs) actas oxidoreductases, while CGFS-type (class II) Grxs act as FeS cluster transferases. Here weshow that the key determinant of Grx function is a distinct loop structure adjacent to theactive site. Engineering of a CxxC/S-type Grx with a CGFS-type loop switched its functionfrom oxidoreductase to FeS transferase. Engineering of a CGFS-type Grx with a CxxC/S-typeloop abolished FeS transferase activity and activated the oxidative half reaction of the oxi-doreductase. The reductive half-reaction, requiring the interaction with a second GSHmolecule, was enabled by switching additional residues in the active site. We explain howsubtle structural differences, mostly depending on the structure of one particular loop, act inconcert to determine Grx function.
Patients with atrial fibrillation (AF) often present with typical angina pectoris and mildly elevated levels of cardiac troponin (non-ST-segment elevation myocardial infarction) during an acute episode of AF. However, in a large proportion of these patients, significant coronary artery disease is excluded by coronary angiography, which suggests that AF itself influences myocardial blood flow. The present review summarizes the effect of AF on the occurrence of ventricular oxidative stress, redox-sensitive signaling pathways and gene expression, and microcirculatory flow abnormalities in the left ventricle.
Despite the extensive ongoing research, there still exist plenty of diseases whose mechanisms have not yet been fully understood, one such example being proteasome-related disorders. Over the last few years, an increasing number of studies have been initiated
to elucidate their driving pathophysiological mechanisms. Determining the systematic effects of genomic alterations occurring in genes encoding 19S proteasome subunits is a key to comprehend the molecular basis of syndromic intellectual disability (ID) pathogenesis and
the subsequent design of new targeted therapies. Therefore, the main objective of my research was to contribute to the identification of potential drivers of syndromic ID, and thereby pave the way for the development of new targeted therapy approaches. In this regard, my aim was to characterize tissue, proteomic and metabolomic changes in cells from patients with PSMC5 mutations and uncover a potential dysregulation of various biochemical and/or inflammatory pathways.
To this end, I undertook a comparative examination of control and patient T cells expanded from peripheral blood mononuclear cells (PBMCs). First, I assessed the proteasome composition in these samples (both in its denaturized and native form), by means of
SDS-PAGE, native PAGE and western-blotting. Moreover, I determined proteasome chymotrypsin-like activity by measure of Suc-LLVY-AMC peptidase activity assay. In addition, I analysed the activation status of the ER stress and mTOR pathway by RT-PCR and SDS-PAGE /western-blotting prior to a subsequent analysis of T-cell markers.
The data show that the investigated p.(Pro320Arg) and p.(Arg201Trp) de novo heterozygous missense mutations in the PSMC5 gene do not cause haploinsufficiency as the steady-state expression level of the PSMC5/Rpt6 full-length protein does not vary between control and patient cells. Further analysis of control and patient T cells under non-reducing conditions revealed that PSMC5/Rpt6 mutants were less efficiently incorporated into 26S proteasome complexes than their wild-type counterparts. The failure to assemble PSMC5/Rpt6 into fully mature proteasomes was associated with a reduced proteasome chymotrypsin-like activity in patient T cells, as determined by in-plate assays. These data unambiguously demonstrate that both of the p.(Pro320Arg) and p.(Arg201Trp) PSMC5 mutations identified in patients suffering from syndromic ID are loss-of-function mutations. Interestingly, my data further show that proteasome dysfunction in these patients was accompanied by abnormalities in mTOR signalling and T-cell differentiation, as determined by western-blotting and flow cytometry, respectively.
Altogether, our data identified for the first time PSMC5 as a disease-causing gene for
a syndromic form of ID. How proteasome dysfunction caused by PSMC5 variants contributes to disease pathogenesis, remains to be fully determined.
Endogenous redox systems not only counteract oxidative damage induced by high levels of hydroxyl radicals (OH·) under pathological conditions, but also shape redox signaling as a key player in the regulation of physiological processes. Second messengers like hydrogen peroxide and nitric oxide, as well as redox enzymes of the Thioredoxin (Trx) family, including Trxs, glutaredoxins (Grxs), and peroxiredoxins (Prxs) modulate reversible, oxidative modifications of proteins. Thereby redox regulation is part of various cellular processes such as the immune response and Trx proteins have been linked in different disorders including inflammatory diseases. Here, we have analyzed the protein distribution of representative oxidoreductases of the Trx fold protein family—Trx1, Grx1, Grx2, and Prx2—in a murine model of allergic asthma bronchiale, as well as their potential therapeutic impact on type-2 driven airway inflammation. Ovalbumin (OVA) sensitization and challenge using the type-2 prone Balb/c mouse strain resulted in increased levels of all investigated proteins in distinct cellular patterns. While concomitant treatment with Grx1 and Prx2 did not show any therapeutic impact on the outcome of the disease, Grx2 or Trx1 treatment before and during the OVA challenge phase displayed pronounced protective effects on the manifestation of allergic airway inflammation. Eosinophil numbers and the type-2 cytokine IL-5 were significantly reduced while lung function parameters profoundly improved. The number of macrophages in the bronchoalveolar lavage (BAL) did not change significantly, however, the release of nitric oxide that was linked to airway inflammation was successfully prevented by enzymatically active Grx2 ex vivo. The Grx2 Cys-X-X-Ser mutant that facilitates de-/glutathionylation, but does not catalyze dithiol/disulfide exchange lost the ability to protect from airway hyper reactivity and to decrease NO release by macrophages, however, it reduced the number of infiltrating immune cells and IL-5 release. Altogether, this study demonstrates that specific redox proteins and particular enzyme activities protect against inflammatory damage. During OVA-induced allergic airway inflammation, administration of Grx2 exerts beneficial and thus potentially therapeutic effects.
The failure of insulin-producingβ-cells is the underlying cause of hyperglycemia in diabetes mellitus.β-cell decay has been linked to hypoxia, chronic inflammation,and oxidative stress. Thioredoxin (Trx) proteins are major actors in redox signaling and essential for signal transduction and the cellular stress response. We haveanalyzed the cytosolic, mitochondrial, and extracellular Trx system proteins in hypoxic and cytokine-induced stress usingβ-cell culture, isolated pancreatic islets, andpancreatic islet transplantation modelling low oxygen supply.Protein levels of cytosolic Trx1 and Trx reductase (TrxR) 1 significantly decreased, while mitochondrial Trx2 and TrxR2 increased upon hypoxia and reox-ygenation. Interestingly, Trx1 was secreted byβ-cells during hypoxia. Moreover, murine and human pancreatic islet grafts released Trx1 upon glucose stimulation.Survival of transplanted islets was substantially impaired by the TrxR inhibitor auranofin.Since a release was prominent upon hypoxia, putative paracrine effects of Trx1 onβ-cells were examined. In fact, exogenously added recombinant hTrx1 mitigatedapoptosis and preserved glucose sensitivity in pancreatic islets subjected to hypoxia and inflammatory stimuli, dependent on its redox activity. Human subjects werestudied, demonstrating a transient increase in extracellular Trx1 in serum after glucose challenge. This increase correlated with better pancreatic islet function.Moreover, hTrx1 inhibited the migration of primary murine macrophages.In conclusion, our study offers evidence for paracrine functions of extracellular Trx1 that improve the survival and function of pancreaticβ-cells.